Premium
Low‐intensity oral anticoagulation in sickle‐cell disease reverses the prethrombotic state: promises for treatment?
Author(s) -
WOLTERS HUGO J.,
CATE HUGO TEN,
THOMAS LAMBERTUS L. M.,
BRANDIES DESIDERIUS P. M.,
ENDE ABRAHAM,
HEIDEN YVONNE,
STATIUS VAN EPS LODEWIJK W.
Publication year - 1995
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1995.tb05607.x
Subject(s) - medicine , disease , intensive care medicine
Summary. Increased plasma levels of prothrombin fragment 1 + 2 (Fl + 2) found in patients with sickle‐cell disease reflect enhanced endogenous thrombin generation. We postulate that hypercoagulability contributes to vaso‐ occlusion. The intensity of acenocoumarol treatment required to reduce the Fl + 2 level to 50% of pretreatment level was investigated in seven patients with symptomatic sickle‐cell anaemia during steady‐state disease for a period of 2 months. All patients had increased levels of Fl + 2 compared with an age‐matched control group. Normalization of the Fl + 2 was achieved at a median INR of 1.64 (range 1.18‐2.2). It is concluded that low‐intensity oral anticoagulation normalizes the hypercoagulability in sickle‐cell disease.